Skip to Main Content

Paper Details

Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma.
J Immunother Cancer
35
2020
B cell repertoires, Cancer, HCC, L1, PD-, PD-1, PD-L1, RNA, chronic hepatitis B or C viral infection, hepatocellular carcinoma, liver cirrhosis, patients, programmed cell death protein 1, programmed death-ligand 1, tissue-resident T cell, tumor, virally-infected
Author NameAffiliation
Ludmila DanilovaBloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine
Ludmila DanilovaJohns Hopkins Medicine Sidney Kimmel Comprehensive Cancer Center
Ludmila DanilovaBloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine
Ludmila DanilovaJohns Hopkins Medicine Sidney Kimmel Comprehensive Cancer Center
Rohan VermaSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
Rohan VermaBloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine
Elana J FertigBloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine
Elana J FertigJohns Hopkins Medicine Sidney Kimmel Comprehensive Cancer Center
Elana J FertigInstitute for Computational Medicine, Mathematical Institute for Data Science, Johns Hopkins University
Elizabeth M JaffeeSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
Elizabeth M JaffeeBloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine
Elizabeth M JaffeeSkip Viragh Center for Pancreatic Cancer, Johns Hopkins University School of Medicine
  • 1 - 12

Datasets

Release 1.2